Literature DB >> 7863269

Rheumatoid arthritis: a medical emergency?

T Pincus1.   

Abstract

Rheumatoid arthritis (RA), previously considered to be a benign controllable disease with a good prognosis in the majority of patients, is now known to be a severe, progressive disease in terms of radiographic damage, severe functional deterioration, progressive work disability and premature mortality. The traditional approach to RA therapy (from less toxic to more toxic drugs) is inadequate and the risk of drug toxicity is generally overestimated while that of severe disease is underestimated. Consequently, aggressive treatment could be considered in an attempt to reverse the inflammation prior to long-term end-organ damage, rather than in response to such damage. As patients with RA may progress to an anticipated 5-year survival similar to that in patients with cardiovascular or neoplastic disease, RA should be viewed as an urgent medical problem--a "medical emergency"--in order to control the long-term consequences of the disease process.

Entities:  

Mesh:

Year:  1994        PMID: 7863269     DOI: 10.3109/03009749409095198

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  11 in total

Review 1.  Advances in use of immunomodulatory agents--a rheumatology perspective.

Authors:  Minyoung Her; Arthur Kavanaugh
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-04-21       Impact factor: 46.802

Review 2.  Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies.

Authors:  Carlomaurizio Montecucco
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.

Authors:  J L Wilson; V Nayanar; J S Walker
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

4.  Value of 99mTc-IgG scintigraphy in the prediction of joint destruction in patients with rheumatoid arthritis of recent onset.

Authors:  M H de Bois; M L Westedt; J W Arndt; K S Wiarda; E A van der Velde; E K Pauwels; F C Breedveld
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

5.  Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients?

Authors:  Izabela Korczowska; Anna Olewicz-Gawlik; Jakub Trefler; Paweł Hrycaj; Jan Krzysztof Łacki
Journal:  Clin Rheumatol       Date:  2007-10-02       Impact factor: 2.980

6.  Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.

Authors:  Bruno Fautrel; Benjamin Granger; Bernard Combe; Alain Saraux; Francis Guillemin; Xavier Le Loet
Journal:  Arthritis Res Ther       Date:  2012-11-19       Impact factor: 5.156

7.  Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.

Authors:  Tânia Silvia Fröde; Patrícia Tenconi; Marilei Reynaud Debiasi; Yara Santos Medeiros
Journal:  Mediators Inflamm       Date:  2002-12       Impact factor: 4.711

8.  Access to rheumatologists among patients with newly diagnosed rheumatoid arthritis in a Canadian universal public healthcare system.

Authors:  Jessica Widdifield; J Michael Paterson; Sasha Bernatsky; Karen Tu; J Carter Thorne; Noah Ivers; Debra Butt; R Liisa Jaakkimainen; Nadia Gunraj; Vandana Ahluwalia; Claire Bombardier
Journal:  BMJ Open       Date:  2014-01-31       Impact factor: 2.692

9.  Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients.

Authors:  Izabela Korczowska; Jan Krzysztof Lacki; Pawel Hrycaj
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

10.  Abnormal directed migration of blood polymorphonuclear leukocytes in rheumatoid arthritis. Potential role in increased susceptibility to bacterial infections.

Authors:  F Aglas; J Hermann; G Egger
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.